Key result
Concomitant use of triptans and SSRIs or serotonergic medications warrants a reevaluation of the FDA warning regarding serotonin syndrome risk.
Key points are not available for this paper at this time.
Answers are grounded in this paper and cite their sources.
May not yet alter prescribing of triptans with SSRIs; leaves open the need for higher-level evidence on serotonin syndrome risk.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Mansuri et al. (2024) studied this question. Concomitant use of triptans and SSRIs or serotonergic medications warrants a reevaluation of the FDA warning regarding serotonin syndrome risk.
Synapse has enriched 10 related papers. Consider them for comparative context: